ARWR
Price
$66.67
Change
-$1.39 (-2.04%)
Updated
Feb 5, 02:24 PM (EDT)
Capitalization
9.53B
Earnings call today
Intraday BUY SELL Signals
STRO
Price
$14.89
Change
+$0.06 (+0.40%)
Updated
Feb 4 closing price
Capitalization
126.85M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARWR vs STRO

Header iconARWR vs STRO Comparison
Open Charts ARWR vs STROBanner chart's image
Arrowhead Pharmaceuticals
Price$66.67
Change-$1.39 (-2.04%)
Volume$200
Capitalization9.53B
Sutro Biopharma
Price$14.89
Change+$0.06 (+0.40%)
Volume$101.07K
Capitalization126.85M
ARWR vs STRO Comparison Chart in %
View a ticker or compare two or three
VS
ARWR vs. STRO commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and STRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ARWR: $68.06 vs. STRO: $14.89)
Brand notoriety: ARWR: Notable vs. STRO: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 80% vs. STRO: 80%
Market capitalization -- ARWR: $9.53B vs. STRO: $126.85M
ARWR [@Biotechnology] is valued at $9.53B. STRO’s [@Biotechnology] market capitalization is $126.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARWR and STRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while STRO’s TA Score has 2 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 3 bearish.
  • STRO’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than STRO.

Price Growth

ARWR (@Biotechnology) experienced а +3.78% price change this week, while STRO (@Biotechnology) price change was -4.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

ARWR is expected to report earnings on Feb 05, 2026.

STRO is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($9.53B) has a higher market cap than STRO($127M). STRO YTD gains are higher at: 28.695 vs. ARWR (2.515). ARWR has higher annual earnings (EBITDA): 165M vs. STRO (-166.43M). ARWR has more cash in the bank: 919M vs. STRO (168M). STRO has less debt than ARWR: STRO (17.7M) vs ARWR (366M). ARWR has higher revenues than STRO: ARWR (829M) vs STRO (106M).
ARWRSTROARWR / STRO
Capitalization9.53B127M7,503%
EBITDA165M-166.43M-99%
Gain YTD2.51528.6959%
P/E RatioN/AN/A-
Revenue829M106M782%
Total Cash919M168M547%
Total Debt366M17.7M2,068%
FUNDAMENTALS RATINGS
ARWR vs STRO: Fundamental Ratings
ARWR
STRO
OUTLOOK RATING
1..100
6325
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
92100
PRICE GROWTH RATING
1..100
3438
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (21) in the Pharmaceuticals Major industry is significantly better than the same rating for ARWR (100) in the Biotechnology industry. This means that STRO’s stock grew significantly faster than ARWR’s over the last 12 months.

STRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ARWR (100) in the Biotechnology industry. This means that STRO’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (92) in the Biotechnology industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that ARWR’s stock grew similarly to STRO’s over the last 12 months.

ARWR's Price Growth Rating (34) in the Biotechnology industry is in the same range as STRO (38) in the Pharmaceuticals Major industry. This means that ARWR’s stock grew similarly to STRO’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for STRO (100) in the Pharmaceuticals Major industry. This means that ARWR’s stock grew significantly faster than STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRSTRO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signal:
Gain/Loss:
STRO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GLASF9.200.24
+2.68%
Glass House Brands Inc.
NPSCY4.370.08
+1.86%
Nippon Steel Corporation
CDPYF28.210.31
+1.09%
Canadian Apartment Properties Real Estate Investment Trust
CBWA16.94N/A
N/A
Commencement Bancorp Inc
GHST0.03N/A
N/A
GHST World Inc.

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been closely correlated with GPCR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARWR jumps, then GPCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-5.66%
GPCR - ARWR
74%
Closely correlated
-3.01%
STRO - ARWR
74%
Closely correlated
+0.40%
OLMA - ARWR
72%
Closely correlated
+0.77%
ROIV - ARWR
71%
Closely correlated
-1.46%
PHGE - ARWR
68%
Closely correlated
-7.36%
More